Volition(VNRX) - 2025 Q2 - Quarterly Results

FORM 8-K Filing Details This section provides essential identification details of VolitionRx Limited as the registrant and outlines its securities and filing status Registrant Information This section provides the fundamental identification details of VolitionRx Limited as the registrant for this Form 8-K filing, including its incorporation state, SEC file number, IRS Employer Identification Number, principal executive offices, and telephone number - Registrant Name: VolitionRx Limited[1] - State of Incorporation: Delaware[1] - Principal Executive Offices: 1489 West Warm Springs Road, Suite 110, Henderson, Nevada 89014[1] Securities and Filing Status This section outlines the company's registered securities and its status regarding specific SEC filing provisions, including its trading symbol and exchange, and confirms it is not an emerging growth company Registered Securities Information | Title of Each Class | Trading Symbol(s) | Name of Each Exchange on which Registered | | :------------------ | :---------------- | :---------------------------------------- | | Common Stock, par value $0.001 per share | VNRX | NYSE American, LLC | - The registrant is not an emerging growth company[3] Current Report Items This section details the company's financial results announcement and lists the accompanying exhibits for the Form 8-K filing Item 2.02 Results of Operations and Financial Condition VolitionRx Limited announced its financial results and business updates for the quarter ended June 30, 2025, through a press release issued on August 14, 2025; a conference call is scheduled for August 15, 2025, to discuss these results, with the press release furnished as Exhibit 99.1 - VolitionRx Limited issued a press release on August 14, 2025, announcing financial results and business updates for the quarter ended June 30, 2025[6] - A conference call is scheduled for August 15, 2025, at 8:30 a.m. U.S. Eastern Time[6] - The press release is furnished as Exhibit 99.1[6] Item 9.01 Financial Statements and Exhibits This section lists the exhibits accompanying the Form 8-K filing, specifically the press release detailing financial results and an interactive data file Exhibits Included | Exhibit Number | Description | | :------------- | :---------- | | 99.1 | Press Release of VolitionRx Limited, dated August 14, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document) | Signatures and Exhibit Index This section includes the official signature confirming the report's authorization and a comprehensive index of all accompanying exhibits Signature The report is officially signed on behalf of VolitionRx Limited by its Chief Executive Officer & President, Cameron Reynolds, on August 14, 2025, confirming due authorization - The report was signed by Cameron Reynolds, Chief Executive Officer & President[11] - Date of signature: August 14, 2025[11] Exhibit Index This section provides a final listing of the exhibits included in the Form 8-K filing, specifically referencing the press release Exhibit Listing | Exhibit Number | Description | | :------------- | :---------- | | 99.1 | Press Release of VolitionRx Limited, dated August 14, 2025 |